Retatrutide vs 5-Amino-1MQ
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. It is investigational, made by Eli Lilly, and not yet FDA approved as of 2026.
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
First, a correction worth making loudly: 5-amino-1MQ is not a peptide. It is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. It blocks an enzyme called NNMT, and in obese mice it produced weight and fat loss without the animals eating less. No human trials have been published.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Retatrutide has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | Retatrutide | 5-Amino-1MQ |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. | NNMT (nicotinamide N-methyltransferase) takes nicotinamide and tags it with a methyl group borrowed from SAM, the cell's main methyl donor, producing 1-methylnicotinamide. In fat tissue, high NNMT activity is thought to drain both NAD+ precursors and SAM, nudging cells toward storing fat. The hypothesis behind 5-amino-1MQ is straightforward: inhibit NNMT, and you preserve NAD+ and SAM inside adipocytes, which shifts them away from fat storage and toward burning energy. The published mouse work showed NNMT inhibition raising intracellular NAD+ and SAM, consistent with that idea. It is a plausible, well-reasoned mechanism, but in humans it remains a hypothesis, not a demonstrated effect. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 50-75 mg daily Once daily, morning |
| Administration | Subcutaneous injection weekly | Subcutaneous injection or oral |
| Typical Duration | Long-term use expected | 4-6 weeks (cycling recommended) |
| Best Time to Take | Morning, same day each week | Morning, fasted |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human evidence is the phase 2 trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023, which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48, hinting the ceiling could be even higher. Among participants with prediabetes at baseline, a large majority returned to normal blood sugar. Side effects were dominated by gastrointestinal issues like nausea, vomiting, and diarrhea, the familiar pattern for this drug class, and were mostly dose-dependent. These are genuinely strong phase 2 results, but they are phase 2: larger and longer phase 3 trials are underway to confirm safety and durability, and retatrutide sold outside of trials is not an approved, quality-controlled medicine. | The headline study (Neelakantan et al.) tested small-molecule NNMT inhibitors in diet-induced obese mice. Treated animals lost weight (roughly 5% from baseline over about 11 days in that work) and shed white adipose mass, with reduced circulating cholesterol and no change in food intake, which points to a metabolic effect rather than appetite suppression. That is genuinely interesting preclinical data. But here is the honest part: the entire evidence base is animal and cell studies. There are no published human clinical trials demonstrating that 5-amino-1MQ causes fat loss, raises energy expenditure, or is safe over time in people. Claims of specific human fat-loss percentages from vendors are not backed by trial data. Treat it as an early-stage research compound, not a proven product. |
Frequently Asked Questions: Retatrutide vs 5-Amino-1MQ
What is the difference between Retatrutide and 5-Amino-1MQ?
Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in a phase 2 trial it produced some of the largest weight loss ever recorded for a drug, up to roughly 24 percent of body weight at the top dose. it is investigational, made by eli lilly, and not yet fda approved as of 2026. 5-Amino-1MQ is a weight loss peptide that first, a correction worth making loudly: 5-amino-1mq is not a peptide. it is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. it blocks an enzyme called nnmt, and in obese mice it produced weight and fat loss without the animals eating less. no human trials have been published. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or 5-Amino-1MQ?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while 5-Amino-1MQ is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and 5-Amino-1MQ be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and 5-Amino-1MQ together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.